(Submitted for publicati6n August 11, 1950; accepted, October 30, 1950) Ferguson's (1, 2) concept of a role for proteolytic enzymes (3) in the mechanisms of blood clotting was that of a weak digestive action "disaggregating" (Pope, 1938) the complex unions of plasma proteins with calcium and thromboplastic phospholipid (probably cephalin), thereby mobilizing or making available these activators and thus, in a sense, "catalyzing" the prothrombin activation (4) . Observations believed to support such a theory included: 1) the clot-aiding effects, particularly referable to the conversion of prothrombin into active thrombin, on adding (crystalline) trypsin (2, 4); and 2) the evidence, not altogether conclusive (4) nor confirmed (5) (6) (7) , that preparations of serum protease (tryptase, plasmin, or fibrinolysin) resemble pancreatic trypsin in many ways although differing significantly in others (3) .
The establishment of crucial data in this, as in all work on the problem of the conversion of prothrombin to thrombin, is technically difficult because of the biochemical complexities, the presence in the natural clotting system (e.g. plasma) of unrecognized factors (some of which have recently been revealed), and questions as to contaminants (the known ones being demonstrable) in even the purest of the isolated reagents available to date (4) . From the start (1939) of our work with the enzyme problem we have accepted the current, and still valid, working hypothesis that, under all ordinary ("physiological ") circumstances, prothrombin requires for its activation free Ca-ions and a phospholipid-containing material for which the terms "thromboplastin" or "thrombokinase" are commonly used. It has more recently been shown by a number of workers that other factors are also involved and evidently must have been unwittingly provided in the test materials of all early experiments. Our own observations (8) that, with very carefully purified and treated reagents, no thrombin could be detected in over 24 hours in mixtures of prothrombin, brain thromboplastin, and calcium salt, but required the addition of another factor or factors which could be supplied in the form of Ware and Seegers' (9) "serum accelerator globulin" (AcG) preparation, caused us to add this reagent to the purified test systems in the present studies. Under these circumstances, as in the past, we feel that our studies are concerned primarily with the basic "thromboplastic" mechanisms.
The present work commences with the confirmation of the clot-aiding effects of trypsin and of serum fibrinolysin on ordinary plasma and supplements this with an experiment on platelet-free plasma. Proceeding thence to the study of thrombin formation from highly purified prothrombin (with added AcG), a number of enzyme preparations, activators, and inhibitors have been tested, in various combinations, in an effort to shed further light upon the possible mechanisms of action of the proteolytic enzymes in such clotting systems. The thromboplastic role of platelets in relation to these phenomena has been given special attention. The weight of evidence eventually leads to the conclusion that whereas trypsin does seem to act with parallelism of its clot-aiding and proteolytic effects, serum fibrinolysin can still aid thrombin formation (in these systems) even when the proteolytic action is reduced greatly or abolished by appropriate enzyme inhibitors. This must suggest another factor in the serum enzyme preparation, the possible nature and mode of action of which are investigated and discussed. shorter clotting-times, with increasing lysin, to 135 sec. "optimum" at 1.5-2.0 mg./ml. lysin; 3) lessening effects with further amounts of enzyme, e.g. 205 sec. at 6.0 mg./ml. In the last test, the clot lysed in one-half hour, whereas at 1.5-2.0 mg./ml. (optimal for clotting), fibrinolysis was incomplete in 48 hours at room temperature. That the inhibitory effect of plasma antilysin is responsible is evident from clot-lysis times for any single concentration of lysin tested in a) plasma clots, b) pure fibrin clots-see Table I As in all plasma experiments, fibrinolytic effects are weak because of natural antilysin and prob- Table III shows, by means of clotting times (sec.) of samples of various thrombic mixtures added to test fibrinogen after the stated incubation periods, the relative amounts of thrombin formation from a purified prothrombin solution. We have presented a critical analysis of this method in a recent publication (4) . In brief, the shortest clottinig time reached measures "complete" conversion of prothrombin to thrombin under the particular test conditions, while the incubation TABLE II "Thromboplastic" action of fibrinolysin in activation of prothrombin in recalcified fibrinogen-free plasma Two and five-tenths ml. plasma (beef: defibrinated at 51°C for one-half hr.), recalcified with 0.25 ml. M/10 CaCI2, with (1) 0.75 ml. borate buffer (control) or (2) 0.75 ml. 1% lysin. After stated incubation periods, 0.25 ml. samples tested with 0.5 ml. 0.5% fibrinogen (F1), noting clotting times (sec.), at 260C, pH = 7.75. period needed for this is a measure of the effectiveness of the activator factors. Since calcium is optimal and a sufficiency of other known accelerators is supplied in the AcG added (perhaps presumptively), the "thromboplastic" factor is believed to be the significant variable. We have not included in the present work any attempt to define a thrombin "unit" or "percentage" (of prothrombin activated), since mere inspection of the data in each experiment suffices clearly to bring out the essential points of comparison. Thus, in the experiments of Table III : 1) No clots in one-half hour shows inadequacy of calcium and AcG alone to activate the purified prothrombin solution; 2) fibrinolysin, in addition, has so little effect as to be practically negligible; 3) platelets, on the other Tpln. A (0.5 ml.) 240"Y 120" 10" 10" 10" 10" 10" hand, contribute a definite "thromboplastic" effect and result in a fairly satisfactory thrombin formation, although inferior to a typical potent tissue thromboplastin (tests 5). The fact that lysin and platelets, acting in conjunction (tests 4), produce the best activation, though not yielding more thrombin (10 sec. clotting time optimum) than in tests 5, argues strongly for a "platelet thromboplastin potentiating" (PTP) action of the enzyme.
Clot-Aiding Effects of Platelets
The designation of the mode of action of platelets as "thromboplastic" in the preceding section would not only be in line with the definition and (14), appearing while the present studies were in progress, claimed that platelets supplied very little thromboplastin, but significant amounts of AcG, and some factor (probably of the type we call "fibrinoplastic" [15] ) which aids the thrombin-fibrinogen reaction, these claims were carefully and repeatedly investigated with our platelet preparations. Table IV is a typical experiment to illustrate how little "AcG-like" action was found in these well-washed platelet preparations. The poor thrombin formation in tests 1 indicates the deficiency of AcG in the chosen prothrombin, so that optimal calcium and tissue thromboplastin are insufficient activators in the hour incubation period. Compare the excellent activation in 4, with plenty of AcG added. Platelets (tests 2) produced relatively little effect, roughly comparable to the weaker AcG addition in 3, which amounts to a concentration of only 1: 2,500,000 in the final thrombic mixture.
Tested on thrombin-fibrinogen mixtures, our platelets showed, if anything, a few seconds' prolongation of clotting times and no "fibrinoplastic" enhancement of clotting at several dilutions. We did find some evidence that a commonly encountered instability of thrombin solutions was apt to be less in the presence of platelets, however.
Effects of Varying Fibrinolysin Concentrations
(Platelets Constant) and of Varying Platelet Concentrations (Fibrinolysin Constant) on Activation of Purified Prothrombin These experiments were performed by our usual technic of following the activation of prothrombin by means of the clotting times for fibrinogen (F2) of samples of the various thrombic mixtures, removed after stated incubation periods. The 2.5 ml. mixtures contained 0.1 ml. Pro.
(0.1%o), 0.25 ml. CaCl2 (50mM), 0.1 ml. AcG (0.1%), and the activators studied. From the series of data obtained, only the clotting-time values at a single incubation period were selected for comparing the effects of varying amounts of the fibrinolysin or platelet activators, and the accompanying graphs are plotted in this way.
In Figure 1 the three curves A, B, C are, respectively, the clotting times (sec.) of samples tested after one, five, and 60 min. incubation. The mixtures all contained 0.1 ml. platelet preparation but the fibrinolysin concentration was varied and is expressed as mg. per 2. by extending the lysin concentration up to 9 mg. it brings out the additional point of an "optimum" for the enzyme effect at about 2.5 mg. (per 2.5 ml.) in this particular experiment. The data clearly show that the "potentiating" effect of fibrinolysin is more marked on the earlier phases of prothrombin activation and does depend upon the enzyme concentration, but, according to the 60 min. data of Figure 1 , C, does not significantly influence the final thrombin yield (shortest clotting times). Figure 2 is an experiment with fixed and approximately optimal fibrinolysin (2.5 mg./2.5 ml.) but varying the amount of platelet preparation between 0 and 1.0 ml./2.5 ml. of thrombic mixture. The one min. incubation samples are selected for the clotting-time test data plotted. Figure 3 shows controls (five min. and 60 min. incubation samples) in an experiment with varying platelets (volumes plotted logarithmically) and no fibrinolysin present. The clotting times are significantly longer than when lysin is added and are expressed in minutes. (13), and 2) platelet thromboplastin potentiating effect, in tests closely similar to those described above. Figure 4 plots, against age of lysin (up to two hours at 37'C), I. fibrinolysis times, which lengthen with weakening enzyme potency, and II. clotting times of five min. incubation samples, which, according to data of the preceding section, give a relative measure of "thromboplastic" potency. It would appear that the two activities of the enzyme preparation weaken at very similar rates. If the clotting-time data are plotted against residual fibrinolytic activity (units computed from a reference curve [13] ), the figure will resemble the descending portion of curves B and B' of Figure 1 , in which dilution, instead of deterioration, was the method of reducing the enzyme activity.
Effects of Protease-Inhibitors on Conversion of
Prothrombin to Thrombin, in Presence of Brain Thromboplastin, Platelets, and Fibrinolysin Preliminary to these studies, extensive experiments were carried out clearly to establish that 1) none of the antienzymes inhibited the thrombinfibrinogen reaction, 2) fibrinolysin (0.1%) had little, if any, effect on strong thrombin ( > 1 u./ml.) but could lengthen clotting times with weak thrombins (< 0.1 u./ml.) due to the opportunity afforded for fibrinogenolysis (cf. [4] ).
Proceeding to the testing of thrombin formation from purified prothrombin with added AcG and optimal calcium and other reagents stated, the data of We have repeatedly confirmed the ability to secure much better thrombin formation in purified prothrombins treated with calcium, AcG, and platelets, when a tiny trace of thrombin was added, far too little merely to add its own clotting-time contribution.
A special test of this phenomenon was made with the purest thrombin available to us. This reagent was obtained by allowing a 0.1 % borate buffer solution of one of Seegers' highly purified prothrombins to activate for several weeks in the refrigerator (4°C) with added calcium salt only. Attempts at Isolation from1 Prothro inbin-Free
Plasma of a Factor Which Potentiates the Thromboplastic Effect of Platelets Oxalated beef plasma was passed five times through Seitz filter pads to render it prothrombinfree by the method of Owren (11) . Tests for thrombin and prothroimibin being entirely negative, the Seitz plasma (S.Pl.) was then subjected to successive fractionation at (a) 20, (b) 30, (c) 40, and (d) 50%o saturation with ammonium sulfate, at room temperature. All precipitates (redissolved in saline) and (e) the final supernatant ("albumin") were dialyzed until sulfate-free.
Tests on dialysates: with the usual prothrombin, AcG, Ca system, with platelets, all proved negative. The fractions were then shaken with chloroform, following the old method (17, 18) for activating fibrinolysin.
Tests on CHCl3-treated dialysates: the usual testing for potentiation of platelet thromboplastin was again carried out, with the result that the only significant acceleration of thrombin conversion was found in Fraction C (30-40%o [NH,] ,SO-).
Control tests: I. CHCl3-treated Fraction C, in same dilution as in preceding tests, showed (a) traces of thrombin, e.g., 0.25 ml. C(dil.) + O.5 ml. F2: clotting time (260 C) 575 sec.; ( b) some fibrinolytic action, e.g., lysis of foregoing clot in about 12 hours. II. The other CHCl.-treated fractions showed no evidence of thrombin or lysin.
In view of the data of the preceding section (Table VII) , the trace of thrombin in CHCl3-treated Fraction C, as well as the fibrinolysin, and possibly other possible factors remaining to be detected, all need critical evaluation.
It was surprising to find any thrombin at all in the above material. Since CHCI3 is known to inactivate antithrombin, we performed some tests which showed a considerable reactivation of thrombin which had lost practically all its activity after incubating 24 hours at room temperature with (a) Seitz-filtered plasma (S.Pl.) or with (b) BaSO4-adsorbed serum. A thrombin-destroying action of CHCI,, seen also with thrombin solution alone, partly (at least) explains the partial recovery. It was found, incidentally, that pancreatic inhibitor retards the antithrombic action and permits the subsequent CHCI1 treatment to give bettter thrombin recoveries.
DISCUSSION
The present investigations confirm earlier observations that both trypsin and serum fibrinolysin (plasmin or tryptase) exert significant clot-aiding effects attributable to participation in the mechanisms of conversion of prothrombin to active thrombin. With purified prothrombin, optimal calcium, and such accessory factors as are supplied with added "serum accelerator globulin," but no added thromboplastin (cell-or tissue-factor), these enzyme preparations have little, if any, "thromboplastic" action of their own, the clotting times of the thrombic mixtures plus purified fibrinogen solution being too long to give significant results. In previous studies (4) with potent tissue thromboplastins, clotting times in control tests, without enzyme, were too short to give more than suggestive evidence that addition of these proteases could "potentiate" the thromboplastic action, particularly in its earlier phases. In the present studies, well-washed platelet preparations, shown to be without significant effects other than those of a relatively weak "thromboplastic" character, were markedly potentiated by the enzyme materials in question.
This PTP ("platelet thromboplastin potentiating") effect of the serum fibrinolysin parallels its lytic activity both in dilution experiments and during deterioration at 37°C. However, protease inhibitors from pancreas (PI) and from serum (AFln) do not abolish the PTP effect, although they do inhibit the enzymic fibrinolysis.
Soybean inhibitor (SBI) has additional "antithromboplastic" effects, even for tissue-and platelet-tlhromboplastins without proteolytic enzyme ( Table V) , so that its effect of at least partly inhibiting the PTP action may very well be due to its antithromboplastic instead of its antilytic effects.
In the case of trypsin, however, all the inhibitors abolish the two effects simultaneously. Thus, the arguments we have previously (4) built up for a "thromboplastic enzyme" mechanism accessory to the thrombin-forming phase of blood clotting, are now still valid only in the artificial test systems with pancreatic trypsin. Failure of correlation of the two effects in tests with appropriate inhibitors (serum antifibrinolysin especially) overthrows a large amount of evidence otherwise strongly suggesting a similar role for the natural serum protease fibrinolysin. The conclusion must be that some other factor must be sought for in the enzyme preparation to account for its thromboplastin potentiating effects.
The possibility that this may be a trace of thrombin is perhaps suggested by the discovery (Table  VII) Tables III and IV. Ware, Fahey, and Seegers (14) found some thrombin formation in platelet-activated mixtures containing stronger prothrombin (330 u./ml.) but none in an hour's incubation with much lower (1.34 u./ml.) prothrombin. If their prothrombin contained the usual trace of thrombin contaminant, these results at the higher concentrations would appear similar to ours, whereas at the lower concentrations the thrombin contaminant may very well have been diluted to insignificance.
Our preliminary attempts to prepare a "p)latelet thromboplastin potentiating" factor, from apparently thrombin-and prothrombin-free Seitz filtered (x 5) plasma, succeeded only in the case of a CHCl3-treated 30-40% saturated (NH4),SO0
Fraction C, in which definite traces of both fibrinolysin and thrombin were demonstrated. The surprising finding of some thrombin here raises some new practical questions. Our suggested explanation is that some thrombin formation in artificially treated plasmas may not be detected, yet result in a "metathrombin" (combination of thrombin with natural antithrombin) from which thrombic activity is recoverable under certain circumstances, e.g., following treatment with chloroform. Many questions as to the state of both prothrombin and thrombin in plasma and in serum are opened up by these new facts and some special studies on these matters are being pursued and have already been mentioned in a preliminary communication (19) .
On casual observation, our PTP factor might appear to be acting like the so-called "accelerator" agents, two and possibly more types of which have occupied the attention of a number of recent investigators. A recent paper (20) in this JOURNAL adequately reviews the current status of these factors and particularly gives experimental evidence that Seegers' "serum accelerator globulin" preparation contains both Alexander's SPCA ("serum prothrombin conversion accelerator") and "labile factor." As we have mentioned earlier, the routine addition of a reasonable amount of serum AcG in our test systems should, we believe, ensure a sufficiency of these "accelerator" factors and make it unnecessary to enter into any discussion of them in the present connection. Rather, we may proceed to consideration of our results in terms of the "thromboplastic" problem. (22) contributes some new technics for analyzing the mechanisms of blood coagulation into three phases. A "prothrombokinase" preparation from a euglobulin precipitate of bovine plasma served for the study of plasma thrombokinase (thromboplastin) formation, with the aid of calcium. A noteworthy point in discussion is . . . "thrombin does not catalyze the activation of prothrombin; but its possible effect on the activation of prothrombokinase remains undetermined." Milstone (23) prepared from the BaSO. adsorbate of bovine plasma globulins a material ("converter fraction") which . . . "hastened both the activation of prothrombin and the conversion of crude prothrombokinase. ... The relation of . . . converter to thrombokinase activity resembles that reported for platelets plus 'globulin' (21) ." In a still more recent paper (24) appearing after this present work was submitted for publication, Milstone reinvestigated the experimental activation of purified prothrombin by platelets, brain thromboplastin, lipoid thromboplastin, and crystalline trypsin, and emphasized the ability of the enzyme to act (a) alone, (b) as potentiator of lipid thromboplastin, and (c) together with platelets (even when amounts of trypsin and platelets were selected neither of which was demonstrably active alone). There are obviously many points of confirmation and parallel interest between Milstone's work and ours, both the present and previously published (4) . However, these serve only to emphasize the complexities of the problem and the final solution mllust await much future investigation. CONCLUSIONS 1. Crytalline trypsin and "purified" serum fibrinolysin accelerate clotting of ordinary recalcified plasma and platelet-free plasma obtained with the silicone technic.
2. These enzymes accelerate anid increase thrombin yields from heat-defibrinated plasma or other crude prothrombins.
3. They have Ino significant effects on the thrombin-fibrinogen reaction (apart from lytic interference) nor uponl the activation of purified prothrombin with Ca and AcG but negligible thromboplastin. 4 . They markedly potentiate platelet thromboplastic action.
5. Well washed platelets are thromboplastic, but negligibly AcG-like, and nonfibrinoplastic.
6. The platelet thromboplastin potentiating (PTP) effect of fibrinolysin shows an optimal enzyme concentration and lessens roughly parallel to weakening of lytic potency by dilution or by thermal deterioration.
7. It is, however, not abolished by effective antiproteases (antilytic) from pancreas (PI) and serum (antifibrinolysin), and only incompletely by soybean inhibitor (SBI), which, however, is antithromboplastic.
8. The PTP effects of trypsin, on the other hand, are completely abolished by the antilytic agents.
9. Very small amounts of thrombin (down to a limit) also have a PTP action, but the fibrinolysin used was practically thrombin-free. 10 . A crude plasma protein fraction obtained at 30-40% (NH) 2SO4 saturation of "prothrombinfree" (Seitz-filtered, x 5) plasma, when treated with CHC1, had PTP effects but contained some thrombin as well as fibrinolysin. 11 . While many of these data support Fergusonl's theory (1) of a clot-aiding role of "thromboplastic enzymes," perhaps still valid for trypsin, the inhibitor data controvert this for fibrinolysin.
After considering the possible significance of thrombin, there remains the possibility of a new PTP factor, possibly the "prothrombokinase converter factor" postulated by Milstone (op. cit.), but apparently unrelated to the "accelerator" factors about which much work has appeared in the recent coagulation literature.
